Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma.
Paczkowska J, Tang M, Wright KT, Song L, Luu K, Shanmugam V, Welsh EL, Weirather JL, Besson N, Olszewski H, Porter BA, Pfaff KL, Redd RA, Cader FZ, Mandato E, Ouyang J, Calabretta E, Bai G, Lawton LN, Armand P, Rodig SJ, Liu XS, Shipp MA. Paczkowska J, et al. Among authors: weirather jl. Nat Commun. 2024 Dec 30;15(1):10740. doi: 10.1038/s41467-024-54512-7. Nat Commun. 2024. PMID: 39737927 Free PMC article.
Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab.
Chen J, Tarantino G, Severgnini M, Baginska J, Giobbie-Hurder A, Weirather JL, Manos M, Russell JD, Pfaff KL, Rodig SJ, Huang AY, Brennick R, Nazzaro M, Hathaway E, Holovatska M, Manuszak C, Ranasinghe S, Liu D, Hodi FS. Chen J, et al. Among authors: weirather jl. Oncoimmunology. 2025 Dec;14(1):2432723. doi: 10.1080/2162402X.2024.2432723. Epub 2024 Dec 19. Oncoimmunology. 2025. PMID: 39699928 Free PMC article.
Next generation sequencing-based MSI scoring predict benefit in mismatch repair deficient tumors treated with nivolumab: follow-up on NCI-MATCH arm Z1D.
Schoenfeld JD, Azad NS, Gross J, Chen L, Overman MJ, Kao K, Jackson LF, Brunnquell D, Bu X, Coppola C, Guan P, Lee J, Sims D, Fuchs R, Weirather JL, Pfaff KL, Gunasti L, Ranasinghe S, Hamilton SR, Wang V, O'Dwyer PJ, Wu CJ, Rodig SJ, Patton DR, Harris L. Schoenfeld JD, et al. Among authors: weirather jl. Clin Cancer Res. 2024 Dec 13. doi: 10.1158/1078-0432.CCR-24-0427. Online ahead of print. Clin Cancer Res. 2024. PMID: 39670863
Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.
Haddox CL, Nathenson MJ, Mazzola E, Lin JR, Baginska J, Nau A, Weirather JL, Choy E, Marino-Enriquez A, Morgan JA, Cote GM, Merriam P, Wagner AJ, Sorger PK, Santagata S, George S. Haddox CL, et al. Among authors: weirather jl. Clin Cancer Res. 2024 Apr 1;30(7):1281-1292. doi: 10.1158/1078-0432.CCR-23-2250. Clin Cancer Res. 2024. PMID: 38236580 Free PMC article. Clinical Trial.
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.
Ricciuti B, Lamberti G, Puchala SR, Mahadevan NR, Lin JR, Alessi JV, Chowdhury A, Li YY, Wang X, Spurr L, Pecci F, Di Federico A, Venkatraman D, Barrichello AP, Gandhi M, Vaz VR, Pangilinan AJ, Haradon D, Lee E, Gupta H, Pfaff KL, Welsh EL, Nishino M, Cherniack AD, Johnson BE, Weirather JL, Dryg ID, Rodig SJ, Sholl LM, Sorger P, Santagata S, Umeton R, Awad MM. Ricciuti B, et al. Among authors: weirather jl. J Clin Oncol. 2024 Apr 10;42(11):1311-1321. doi: 10.1200/JCO.23.00580. Epub 2024 Jan 11. J Clin Oncol. 2024. PMID: 38207230 Free PMC article.
EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade.
Tabasum S, Thapa D, Giobbie-Hurder A, Weirather JL, Campisi M, Schol PJ, Li X, Li J, Yoon CH, Manos MP, Barbie DA, Hodi FS. Tabasum S, et al. Among authors: weirather jl. Cancer Immunol Res. 2023 Nov 1;11(11):1493-1507. doi: 10.1158/2326-6066.CIR-23-0171. Cancer Immunol Res. 2023. PMID: 37728484 Free PMC article.
A cellular and spatial atlas of TP53 -associated tissue remodeling in lung adenocarcinoma.
Zhao W, Kepecs B, Mahadevan NR, Segerstolpe A, Weirather JL, Besson NR, Giotti B, Soong BY, Li C, Vigneau S, Slyper M, Wakiro I, Jane-Valbuena J, Ashenberg O, Rotem A, Bueno R, Rozenblatt-Rosen O, Pfaff K, Rodig S, Hata AN, Regev A, Johnson BE, Tsankov AM. Zhao W, et al. Among authors: weirather jl. bioRxiv [Preprint]. 2024 Feb 14:2023.06.28.546977. doi: 10.1101/2023.06.28.546977. bioRxiv. 2024. PMID: 37425718 Free PMC article. Preprint.
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013.
Ademuyiwa FO, Gao F, Street CR, Chen I, Northfelt DW, Wesolowski R, Arora M, Brufsky A, Dees EC, Santa-Maria CA, Connolly RM, Force J, Moreno-Aspitia A, Herndon JM, Carmody M, Davies SR, Larson S, Pfaff KL, Jones SM, Weirather JL, Giobbie-Hurder A, Rodig SJ, Liu Z, Hagemann IS, Sharon E, Gillanders WE. Ademuyiwa FO, et al. Among authors: weirather jl. NPJ Breast Cancer. 2022 Dec 30;8(1):134. doi: 10.1038/s41523-022-00500-3. NPJ Breast Cancer. 2022. PMID: 36585404 Free PMC article.
37 results